Movatterモバイル変換


[0]ホーム

URL:


PE20130480A1 - HETEROCYCLIC COMPOUNDS AS ANTAGONISTS OF THE PERIPHERAL OPIOID RECEPTOR - Google Patents

HETEROCYCLIC COMPOUNDS AS ANTAGONISTS OF THE PERIPHERAL OPIOID RECEPTOR

Info

Publication number
PE20130480A1
PE20130480A1PE2012002295APE2012002295APE20130480A1PE 20130480 A1PE20130480 A1PE 20130480A1PE 2012002295 APE2012002295 APE 2012002295APE 2012002295 APE2012002295 APE 2012002295APE 20130480 A1PE20130480 A1PE 20130480A1
Authority
PE
Peru
Prior art keywords
opioid receptor
peripheral opioid
antagonists
heterocyclic compounds
bromide
Prior art date
Application number
PE2012002295A
Other languages
Spanish (es)
Inventor
Alfred A Avey
Harold D Doshan
Julio Perez
Yakov Rotshteyn
Appavu Chandrasekaran
Original Assignee
Progenics Pharm Inc
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=39790857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130480(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Progenics Pharm Inc, Wyeth LlcfiledCriticalProgenics Pharm Inc
Publication of PE20130480A1publicationCriticalpatent/PE20130480A1/en

Links

Classifications

Landscapes

Abstract

Translated fromSpanish

SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE: R1 ES -OH, -OS(O)2OH; R2 ES -OH; R2' ES H O R2 Y R2' FORMAN JUNTOS UN GRUPO OXO; X¯ ES UN ANION SELECCIONADO ENTRE CLORURO, YODURO, BROMURO, FLUORURO, SULFATO, BISULFATO, TARTRATO, NITRATO, CITRATO, FUMARATO, ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA. UN COMPUESTO PREFERIDO ES BROMURO DE (5 ALFA, 6 ALFA)-17-CICLOPROPILMETIL-17-METIL-4,5-EPOXI-3,6,14-TRIHIDROXI-MORFINAN DICHO COMPUESTO ES UN ANTAGONISTA DEL RECEPTOR OPIOIDE PERIFERICO UTIL EN EL TRATAMIENTO, PREVENCION, ALIVIO, RETARDO O REDUCCION DE LA SEVERIDAD Y/O INCIDENCIA DE LOS EFECTOS COLATERALES ASOCIADOS A LA ADMINISTRACION DE OPIOIDES.REFERS TO A COMPOUND OF FORMULA (I) WHERE: R1 IS -OH, -OS (O) 2OH; R2 IS -OH; R2 'IS HO R2 AND R2' TOGETHER FORM AN OXO GROUP; X¯ IS AN ANION SELECTED FROM CHLORIDE, IODIDE, BROMIDE, FLUORIDE, SULPHATE, BISULPHATE, TARTRATE, NITRATE, CITRATE, FUMARATE, AMONG OTHERS. ALSO REFERRED TO A PHARMACEUTICAL COMPOSITION. A PREFERRED COMPOUND IS (5 ALPHA, 6 ALPHA) -17-CYCLOPROPYLMEthyl-17-METHYL-4,5-EPOXY-3,6,14-TRIHYDROXY-MORPHINAN BROMIDE ANTAGONIST OF THE PERIPHERAL OPIOID RECEPTOR USEFUL IN THE TRIPS. , PREVENTION, RELIEF, DELAY OR REDUCTION OF THE SEVERITY AND / OR INCIDENCE OF THE SIDE EFFECTS ASSOCIATED WITH THE ADMINISTRATION OF OPIOIDS.

PE2012002295A2007-03-292008-03-28 HETEROCYCLIC COMPOUNDS AS ANTAGONISTS OF THE PERIPHERAL OPIOID RECEPTORPE20130480A1 (en)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
US92112307P2007-03-292007-03-29

Publications (1)

Publication NumberPublication Date
PE20130480A1true PE20130480A1 (en)2013-05-08

Family

ID=39790857

Family Applications (2)

Application NumberTitlePriority DateFiling Date
PE2012002295APE20130480A1 (en)2007-03-292008-03-28 HETEROCYCLIC COMPOUNDS AS ANTAGONISTS OF THE PERIPHERAL OPIOID RECEPTOR
PE2008000574APE20090700A1 (en)2007-03-292008-03-28 HETEROCYCLIC COMPOUNDS AS ANTAGONISTS OF THE PERIPHERAL OPIOID RECEPTOR

Family Applications After (1)

Application NumberTitlePriority DateFiling Date
PE2008000574APE20090700A1 (en)2007-03-292008-03-28 HETEROCYCLIC COMPOUNDS AS ANTAGONISTS OF THE PERIPHERAL OPIOID RECEPTOR

Country Status (14)

CountryLink
US (2)US8546418B2 (en)
EP (2)EP3064503A1 (en)
JP (2)JP5461386B2 (en)
AR (1)AR065877A1 (en)
AU (2)AU2008233129B2 (en)
CA (2)CA2682125C (en)
CL (2)CL2008000905A1 (en)
ES (1)ES2570374T3 (en)
MX (1)MX2009010552A (en)
PA (1)PA8774201A1 (en)
PE (2)PE20130480A1 (en)
PL (1)PL2137191T3 (en)
TW (2)TWI466671B (en)
WO (1)WO2008121348A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
HRP20150037T4 (en)2003-04-082022-09-02Progenics Pharmaceuticals, Inc. PHARMACEUTICAL FORMULATIONS CONTAINING METHYLNALTREXONE
AR057325A1 (en)2005-05-252007-11-28Progenics Pharm Inc SYNTHESIS OF (S) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
AR057035A1 (en)2005-05-252007-11-14Progenics Pharm Inc SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
TW200815451A (en)2006-08-042008-04-01Wyeth Corp6-carboxy-normorphinan derivatives, synthesis and uses thereof
TWI489984B (en)2006-08-042015-07-01Wyeth Corp Formulations for parenteral delivery of compounds and uses thereof
CN101801979A (en)2007-03-292010-08-11普罗热尼奇制药公司Crystalline forms of -N-methylnaltrexone bromide and uses thereof
EP3064503A1 (en)2007-03-292016-09-07Progenics Pharmaceuticals, Inc.Peripheral opioid receptor antagonists and uses thereof
WO2008121860A1 (en)2007-03-292008-10-09WyethPeripheral opioid receptor and antagonists and uses thereof
US8471022B2 (en)2008-02-062013-06-25Progenics Pharmaceuticals, Inc.Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
CA2676881C (en)2008-09-302017-04-25WyethPeripheral opioid receptor antagonists and uses thereof
US8637538B1 (en)2012-12-142014-01-28Trevi Therapeutics, Inc.Methods for treatment of pruritis
US8987289B2 (en)2012-12-142015-03-24Trevi Therapeutics, Inc.Methods for treating pruritus
US20140179727A1 (en)2012-12-142014-06-26Trevi Therapeutics, Inc.Methods for treating pruritus
KR102010454B1 (en)*2012-12-262019-08-13삼성전자주식회사Scan flip-flop, method thereof and device including the same
WO2016014864A1 (en)*2014-07-232016-01-28Salix Pharmaceuticals, Inc.Hydroxy-(r)-2,2'-bismethylnal trexones and uses thereof
HRP20210606T1 (en)2015-04-232021-05-28Trevi Therapeutics, Inc. COMPOUNDS FOR THE TREATMENT OF ITCHING CONDITION
CN118512452A (en)2018-07-232024-08-20特雷维治疗股份有限公司 Treatment of chronic cough, shortness of breath, and difficulty breathing
WO2021142288A1 (en)2020-01-102021-07-15Trevi Therapeutics, Inc.Methods of administering nalbuphine
EP4577667A2 (en)*2022-08-252025-07-02Biosynth GmbHProcedure for production of opioid-antagonist-releasing compounds and their use as a medicine

Family Cites Families (252)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
DE1420015B1 (en)*1959-10-161971-08-26Boehringer Sohn Ingelheim 2'-Hydroxy-5,9-dimethyl-6,7-benzomorphane
GB1202148A (en)1968-03-061970-08-12Sankyo CoPharmaceutical compositions
US3854480A (en)1969-04-011974-12-17Alza CorpDrug-delivery system
US3884916A (en)*1971-03-301975-05-20Janssen Pharmaceutica Nv2,2-Diaryl-4-(4-aryl-4-hydroxy-piperidino)-butyramides
US3714159A (en)*1971-03-301973-01-30Janssen Pharmaceutica Nv2,2-diaryl-4-(4'-aryl-4'-hydroxy-piper-idino)-butyramides
US4326074A (en)*1972-09-221982-04-20William H. Rorer, Inc.Amidinoureas
US4025652A (en)*1975-03-311977-05-24William H. Rorer, Inc.Amidinoureas
US3937801A (en)*1973-07-101976-02-10American Home Products CorporationReducing the incidence of gastrointestinal side effects during the treatment of inflammatory conditions with antiinflammatory drugs
US4060635A (en)1975-03-311977-11-29William H. Rorer, Inc.Amidinoureas for treating diarrhea
US4203920A (en)*1975-03-311980-05-20William H. Rorer, Inc.Amidinoureas
US4072686A (en)*1975-04-161978-02-07G. D. Searle & Co.1-(3,3,3-Triarylalkyl)-4-phenyl-piperidinealkanols
US4066654A (en)*1975-04-161978-01-03G. D. Searle & Co.1-triarylalkyl-4-phenyl-4-piperidine carboxylic acids and derivatives
US3996214A (en)1976-02-231976-12-07G. D. Searle & Co.5-(1,1-Diphenyl-4-(cyclic amino) but-2-trans-en-1-yl)-2-alkyl-1,3,4-oxadiazoles and intermediates thereto
US4013668A (en)*1976-03-101977-03-22G. D. Searle & Co.5-(1,1-diphenyl-3-(5- or 6-hydroxy-2-azabicyclo(2.2.2)oct-2-yl)propyl)-2-alkyl-1,3,4-oxadiazoles and related compounds
US4012393A (en)*1976-03-221977-03-15G. D. Searle & Co.2-[5-(CYCLIC AMINO) ETHYL-10,11-DIHYDRO-5H-dibenzo[a,d]-cyclohepten-5- yl]-5
US4115400A (en)1976-05-271978-09-19Eli Lilly And Company1-Azoniabicyclo[3.1.0]hexanes
GB1593191A (en)1977-03-231981-07-15Reckitt & Colmann Prod LtdDerivatives of morphine
US4125531A (en)1977-04-181978-11-14G. D. Searle & Co.2-Substituted-1-azabicyclo[2.2.2]octanes
US4069223A (en)*1977-05-021978-01-17G. D. Searle & Co.4-Aminomethyl-1-(3,3,3-triarylpropyl)-4-arylpiperidine and derivatives thereof
US4116963A (en)1977-05-231978-09-26G.D. Searle & Co.3,3,3-triarylalkyl-4-phenylalkyl-4-hydroxy piperidines and related compounds
US4194045A (en)*1977-12-271980-03-18G. D. Searle & Co.1-(3,3-Diaryl-3-oxadiazolalkyl)-4-phenyl-4-piperidinomethanols and related compounds
US4176186A (en)1978-07-281979-11-27Boehringer Ingelheim GmbhQuaternary derivatives of noroxymorphone which relieve intestinal immobility
JPS5535031A (en)*1978-09-041980-03-11Shin Etsu Chem Co LtdEnteric coating composition
US4311833A (en)*1979-03-061982-01-19Daicel Chemical Industries Ltd.Process for preparing ethylcarboxymethylcellulose
US4277605A (en)1980-03-071981-07-07Bristol-Myers CompanyChemical compounds
US4322426A (en)*1980-04-281982-03-30E. I. Du Pont De Nemours And Company17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists
US4675189A (en)1980-11-181987-06-23Syntex (U.S.A.) Inc.Microencapsulation of water soluble active polypeptides
US4466968A (en)1980-11-241984-08-21Dermall, Ltd.Method for prophylaxis or treatment of emesis and nausea
US4427676A (en)*1980-12-191984-01-24John Wyeth & Brother Ltd.Thiomorpholine derivatives
US4377568A (en)*1981-08-121983-03-22Merck Sharp & Dohme (I.A.) Corp.Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DK150008C (en)1981-11-201987-05-25Benzon As Alfred PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL ORAL POLYDEPOT PREPARATION
US4987136A (en)*1982-03-161991-01-22The Rockefeller UniversityMethod for controlling gastrointestinal dysmotility
US4870084A (en)1982-03-161989-09-26Pfizer Inc.Bicyclic benzo fused pyran compounds used for nausea treatment and prevention
JPS59500418A (en)1982-03-161984-03-15ザ ロツクフエラ− ユニバ−シテイ How to recover from gastrointestinal dysfunction
JPS58142090U (en)1982-03-201983-09-24幸和産業株式会社 Interlocking prize ball feeder for pachinko machines
US4430327A (en)*1982-05-181984-02-07Eli Lilly And CompanyMethod for treating pregnant females for pain and anxiety
US4457907A (en)1982-08-051984-07-03Clear Lake Development GroupComposition and method for protecting a therapeutic drug
US4533739A (en)1982-10-121985-08-06G. D. Searle & Co.2-[(Aminophenyl and amidophenyl)amino]-1-azacycloalkanes having antidiarrheal activity
US4518433A (en)*1982-11-081985-05-21Fmc CorporationEnteric coating for pharmaceutical dosage forms
US4452775A (en)1982-12-031984-06-05Syntex (U.S.A.) Inc.Cholesterol matrix delivery system for sustained release of macromolecules
US4462839A (en)1983-06-161984-07-31Fmc CorporationEnteric coating for pharmaceutical dosage forms
US4556552A (en)1983-09-191985-12-03Colorcon, Inc.Enteric film-coating compositions
US4615885A (en)1983-11-011986-10-07Terumo Kabushiki KaishaPharmaceutical composition containing urokinase
US4689332A (en)1984-04-091987-08-25Research CorporationGrowth regulation and related applications of opioid antagonists
US5266574A (en)1984-04-091993-11-30Ian S. ZagonGrowth regulation and related applications of opioid antagonists
US4666716A (en)1984-09-041987-05-19Richardson-Vicks Inc.Antidiarrheal compositions and use thereof
JPS6229515A (en)1985-07-301987-02-07Shinjiro TsujiMethod for film-coating of hard capsule
JPH0676314B2 (en)1985-09-301994-09-28花王株式会社 Suppository base and suppository
US4824853A (en)*1985-10-111989-04-25Janssen Pharmaceutica N.V.α,α-diaryl-4-aryl-4-hydroxy-1-piperidinebutanamide, N-oxides and method of treating diarrhea
US4806556A (en)*1985-12-121989-02-21Regents Of The University Of MinnesotaGut-selective opiates
US4730048A (en)*1985-12-121988-03-08Regents Of The University Of MinnesotaGut-selective opiates
US4719215A (en)1986-03-071988-01-12University Of ChicagoQuaternary derivatives of noroxymorphone which relieve nausea and emesis
US4861781A (en)1986-03-071989-08-29The University Of ChicagoQuaternary derivatives of noroxymorphone which relieve nausea and emesis
DE3609073C2 (en)1986-03-181995-08-10Hans J Prof Dr Rer Nat Schmitt Measuring device for non-invasive detection of peripheral drainage and flow disorders in human extremities
US4990521A (en)*1986-07-031991-02-05Janssen Pharmaceutica4-(aroylamino)piperidine-butanimide derivatives
AU604052B2 (en)1986-08-281990-12-06Enzacor Properties LimitedAnimal growth promotant
US5597564A (en)*1986-08-281997-01-28Enzacor Properties LimitedMethod of administering a microgranular preparation to the intestinal region of animals
US4888346A (en)1986-10-071989-12-19Bernard BihariMethod for the treatment of persons infected with HTLV-III (AIDS) virus
US4765978A (en)1986-12-161988-08-23Schering CorporationNovel vaginal suppository
FR2609632B1 (en)1987-01-211991-03-29Shelly Marc NOVEL THERAPEUTIC APPLICATION OF 17- (CYCLOPROPYLMETHYL) -4,5-EPOXY-3,14-DIHYDROXYMORPHINON-6-ONE AND PHARMACEUTICAL COMPOSITIONS FOR THIS USE
NL8700842A (en)1987-04-101988-11-01Duphar Int Res
US4891379A (en)*1987-04-161990-01-02Kabushiki Kaisha Kobe SeikoshoPiperidine opioid antagonists
CA1315689C (en)1987-09-031993-04-06Leon I. GoldbergQuarternary derivatives of noroxymorphone which relieve nausea and emesis
DE3780819T2 (en)1987-09-101993-01-14Univ Chicago QUATERNAERE DERIVATIVES OF NOROXYMORPHONE FOR THE TREATMENT OF Nausea AND Vomiting.
US4912114A (en)*1988-03-181990-03-27Sandoz Ltd.Morphinan derivatives
US4774230A (en)1988-03-261988-09-27Ivax Laboratories, Inc.Glucuronic acid derivatives of opioid antagonists
EP0350221B1 (en)*1988-06-301996-04-17Astra AktiebolagDermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same
EP0352361A1 (en)1988-07-291990-01-31The Rockefeller UniversityMethod of treating patients suffering from chronic pain or chronic cough
US4999342A (en)*1988-08-161991-03-12Ortho Pharmaceutical CorporationLong lasting contraceptive suppository composition and methods of use
US4857533A (en)1988-12-151989-08-15Baker Cummins Pharmaceuticals, Inc.Method of treatment for autoimmune diseases
US4863928A (en)1989-01-041989-09-05Baker Cummins Pharmaceuticals, Inc.Method of treatment for arthritic and inflammatory diseases
US5102887A (en)1989-02-171992-04-07Arch Development CorporationMethod for reducing emesis and nausea induced by the administration of an emesis causing agent
US5116868A (en)*1989-05-031992-05-26The Johns Hopkins UniversityEffective ophthalmic irrigation solution
US5133974A (en)1989-05-051992-07-28Kv Pharmaceutical CompanyExtended release pharmaceutical formulations
US4965269A (en)1989-12-201990-10-23Ab HassleTherapeutically active chloro substituted benzimidazoles
US5236947A (en)1990-02-281993-08-17Jouveinal S.A.Propanamines, their pharmacological properties and their application as an antidiarrheal
JPH0813748B2 (en)1990-04-231996-02-14帝國製薬株式会社 Colon disintegrating polypeptide oral preparation
HU227346B1 (en)1990-05-112011-04-28PfizerProcess for producing synergetic pharmaceutical composition
JP3160862B2 (en)1990-11-152001-04-25雪印乳業株式会社 Bone-fortified foods, feeds and pharmaceuticals
JPH04230625A (en)*1990-12-271992-08-19Standard Chem & Pharmaceut Corp LtdMethod for production of finely dispersed tablet composition consisting of microcapsule containing sprayed and dried sodium dichlofenac and having enteric coating
WO1992014364A1 (en)1991-02-251992-09-03Conan KornetskyOpiate receptor antagonist modulates hyperkinetic movement disorder
US5250542A (en)1991-03-291993-10-05Eli Lilly And CompanyPeripherally selective piperidine carboxylate opioid antagonists
US5270328A (en)1991-03-291993-12-14Eli Lilly And CompanyPeripherally selective piperidine opioid antagonists
CA2064373C (en)1991-03-292005-08-23Buddy Eugene CantrellPiperidine derivatives
US5159081A (en)1991-03-291992-10-27Eli Lilly And CompanyIntermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US5220017A (en)1991-04-101993-06-15Merck & Co., Inc.Cholecystokinin antagonists
JPH06508371A (en)*1991-06-211994-09-22ユニバーシティー オブ シンシナティ Orally administrable therapeutic protein and its production method
US5407686A (en)*1991-11-271995-04-18Sidmak Laboratories, Inc.Sustained release composition for oral administration of active ingredient
US5614219A (en)*1991-12-051997-03-25Alfatec-Pharma GmbhOral administration form for peptide pharmaceutical substances, in particular insulin
US5256154A (en)1992-01-311993-10-26Sterling Winthrop, Inc.Pre-filled plastic syringes and containers and method of terminal sterilization thereof
JPH05213763A (en)1992-02-101993-08-24Sanwa Kagaku Kenkyusho Co LtdReadily absorbable activated calcium preparation
NL9220019A (en)1992-04-101994-04-05Vnii Med Polimerov PHARMACEUTICAL COMPOSITION.
US5686072A (en)1992-06-171997-11-11Board Of Regents, The University Of TexasEpitope-specific monoclonal antibodies and immunotoxins and uses thereof
USRE36547E (en)*1992-09-212000-02-01Albert Einstein College Of Medicine Of Yeshiva UniversityMethod of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5512578A (en)*1992-09-211996-04-30Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva UniversityMethod of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5580876A (en)1992-09-211996-12-03Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva UniversityMethod of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US6096756A (en)*1992-09-212000-08-01Albert Einstein College Of Medicine Of Yeshiva UniversityMethod of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5472943A (en)1992-09-211995-12-05Albert Einstein College Of Medicine Of Yeshiva University,Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
ATE215565T1 (en)1992-10-282002-04-15Genentech Inc USE OF ANTI-VEGF ANTIBODIES TO TREAT CANCER
SG52402A1 (en)*1992-12-221998-09-28Univ CincinnatiOral administration of immunologically active biomolecules and other therapeutic proteins
DE4303214A1 (en)1993-02-041994-08-11Wolfgang MarksTreatment of diseases of viral, viroidal or oncogenic origin by steroid saponins or their aglycones
US5585348A (en)1993-02-101996-12-17Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva UniversityUse of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia
US5656290A (en)1993-02-261997-08-12The Procter & Gamble CompanyBisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5391372A (en)*1993-06-281995-02-21Campbell; ElizabethMethods of treating colic and founder in horses
CA2143864C (en)1993-07-232006-01-24Hiroshi NagaseMorphinan derivatives and pharmaceutical use thereof
GB2281205A (en)1993-08-241995-03-01Euro Celtique SaOral opioid analgesic
SE9303744D0 (en)*1993-11-121993-11-12Astra Ab Pharmaceutical emulsion
US5434171A (en)1993-12-081995-07-18Eli Lilly And CompanyPreparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates
US6190691B1 (en)*1994-04-122001-02-20Adolor CorporationMethods for treating inflammatory conditions
DE69503126T2 (en)1994-05-051998-11-12Beckman Instruments Inc REPETITIVE OLIGONUCLEOTIDE MATRIX
IT1269826B (en)1994-05-241997-04-15Paolo Minoia USE OF OPTIACEAN ANTAGONISTS AND CALCIUM SALTS FOR THE PREPARATION OF MEDICATIONS FOR THE TREATMENT OF ENDORPHINE-MEDIATED PATHOLOGICAL FORMS
US5536507A (en)1994-06-241996-07-16Bristol-Myers Squibb CompanyColonic drug delivery system
US5866154A (en)*1994-10-071999-02-02The Dupont Merck Pharmaceutical CompanyStabilized naloxone formulations
US5614222A (en)*1994-10-251997-03-25Kaplan; Milton R.Stable aqueous drug suspensions and methods for preparation thereof
US5965161A (en)1994-11-041999-10-12Euro-Celtique, S.A.Extruded multi-particulates
US5578725A (en)1995-01-301996-11-26Regents Of The University Of MinnesotaDelta opioid receptor antagonists
ES2094694B1 (en)*1995-02-011997-12-16Esteve Quimica Sa NEW PHARMACEUTICALLY STABLE FORMULATION OF A COMPOUND OF BENZMIDAZOLE AND ITS PROCESS OF OBTAINING.
US6096763A (en)1995-02-232000-08-01Merck & Co., Inc.α1a adrenergic receptor antagonists
US6025154A (en)*1995-06-062000-02-15Human Genome Sciences, Inc.Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US5714586A (en)*1995-06-071998-02-03American Cyanamid CompanyMethods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5821219A (en)1995-08-111998-10-13Oregon Health Sciences UniversityOpioid antagonists and methods of their use
GB9517001D0 (en)1995-08-181995-10-18Denny WilliamEnediyne compounds
US5804595A (en)1995-12-051998-09-08Regents Of The University Of MinnesotaKappa opioid receptor agonists
PT780372E (en)1995-12-212002-04-29Syngenta Participations Ag DERIVATIVES OF 3-AMINO-2-MERCAPTOBENZOIC ACID AND PROCESSES FOR THEIR PREPARATION
EP0977558B1 (en)1996-02-152003-10-01Janssen Pharmaceutica N.V.Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors
WO1997033566A2 (en)1996-03-121997-09-18Alza CorporationComposition and dosage form comprising opioid antagonist
US6136780A (en)1996-03-292000-10-24The Penn State Research FoundationControl of cancer growth through the interaction of [Met5 ]-enkephalin and the zeta (ζ) receptor
US20040024006A1 (en)*1996-05-062004-02-05Simon David LewOpioid pharmaceutical compositions
DE19651551C2 (en)1996-12-112000-02-03Klinge Co Chem Pharm Fab Opioid antagonist-containing galenic formulation
US20010036469A1 (en)1997-01-132001-11-01Gooberman Lance L.Opiate antagonist implant and process for preparation therefor
US6884879B1 (en)*1997-04-072005-04-26Genentech, Inc.Anti-VEGF antibodies
GB9801231D0 (en)*1997-06-051998-03-18Merck & Co IncA method of treating cancer
HU9701081D0 (en)*1997-06-231997-08-28Gene Research Lab Inc NPharmaceutical composition of antitumoral activity
US6525038B1 (en)*1997-06-242003-02-25Werner KreutzSynergistic compositions for the selective control of tumor tissue
US6353004B1 (en)*1997-07-142002-03-05Adolor CoporationPeripherally acting anti-pruritic opiates
US6096764A (en)1997-08-212000-08-01Eli Lilly And CompanyMethods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration
US6099853A (en)1997-09-042000-08-08Protein ExpressVaginal suppository vaccine for urogenital infections
AU2003204844B2 (en)1997-11-032007-06-07Arch Development CorporationUse of methylnaltrexone and related compounds
US6559158B1 (en)1997-11-032003-05-06Ur Labs, Inc.Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US20030158220A1 (en)1997-11-032003-08-21Foss Joseph F.Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US5972954A (en)1997-11-031999-10-26Arch Development CorporationUse of methylnaltrexone and related compounds
US6274591B1 (en)*1997-11-032001-08-14Joseph F. FossUse of methylnaltrexone and related compounds
US5943967A (en)1997-11-141999-08-31Morgan Marshall Industries, Inc.Mobile pharmacy shelving
US6777534B1 (en)1997-12-092004-08-17Children's Medical Center CorporationPeptide antagonists of vascular endothelial growth factor
NZ505193A (en)*1997-12-222003-03-28Euro Celtique SOpioid agonist/antagonist combinations
EP0930334A1 (en)1998-01-161999-07-21Quest International B.V.Polysaccharide conjugate capable of binding cellulose
GB9802251D0 (en)1998-02-031998-04-01Ciba Geigy AgOrganic compounds
CN1140272C (en)*1998-04-032004-03-03味之素株式会社 antineoplastic agent
US6359111B1 (en)*1998-05-282002-03-19Neorx CorporationOpioid receptor targeting
HN1999000149A (en)*1998-09-092000-01-12Pfizer Prod Inc DERIVATIVES OF 4,4-BIARILPIPERIDINA
US20010010919A1 (en)1998-10-132001-08-02David K. GrandyOpioid antagonists and methods of their use
US6194382B1 (en)*1999-03-032001-02-27Albert Einstein College Of Medicine Of Yeshiva UniversityMethod and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
JP4049477B2 (en)1999-03-232008-02-20大鵬薬品工業株式会社 Side effect reducing agent
US7129265B2 (en)1999-04-232006-10-31Mason R PrestonSynergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy
US6171620B1 (en)1999-04-272001-01-09Health Research, Inc.Method of enhancing the efficacy of anti-tumor agents
AU4564200A (en)1999-04-292000-11-17Aventis Pharma S.A.Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6833349B2 (en)1999-06-082004-12-21Regeneron Pharmaceuticals, Inc.Methods of treating inflammatory skin diseases
US20020068712A1 (en)1999-07-232002-06-06Troy StevensUse of decreasing levels of functional transient receptor potential gene product
US20030105121A1 (en)1999-07-272003-06-05Bernard BihariMethod of preventing lipodystrophy syndrome or reversing a pre-existing syndrome in HIV-infected patients being treated with antiretroviral agents
EP1206264A2 (en)1999-08-252002-05-22Barrett R. CooperCompositions and methods for treating opiate intolerance
AU781058B2 (en)1999-08-312005-05-05Grunenthal GmbhDelayed-action form of administration containing tramadol saccharinate
US6451806B2 (en)1999-09-292002-09-17Adolor CorporationMethods and compositions involving opioids and antagonists thereof
DK1225897T3 (en)1999-11-012005-01-10John Rhodes Composition for the treatment of constipation and irritable colon
DE69927688T2 (en)*1999-11-042006-07-06Institut Gustave Roussy Antiviral agent in combination with radiotherapy for use in the treatment of cancer
AU4136901A (en)1999-11-292001-06-18Adolor CorporationNovel methods for the treatment and prevention of dizziness and pruritus
US6384044B1 (en)1999-11-292002-05-07Bernard BihariMethod of treating cancer of the prostate
US6469030B2 (en)1999-11-292002-10-22Adolor CorporationMethods for the treatment and prevention of ileus
JP5079961B2 (en)1999-11-292012-11-21アドラー コーポレーション A novel method for the treatment and prevention of ileus
IL149600A0 (en)1999-11-292002-11-10Adolor CorpNovel methods and compositions involving opioids and antagonists thereof
US6545010B2 (en)2000-03-172003-04-08Aventis Pharma S.A.Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
US20010046968A1 (en)2000-03-232001-11-29Zagon Ian S.Opioid growth factor modulates angiogenesis
US6967075B2 (en)2000-04-072005-11-22Schering CorporationHCV replicase complexes
WO2001085257A2 (en)2000-05-052001-11-15Pain Therapeutics, Inc.Opioid antagonist compositions and dosage forms
DK1296714T3 (en)*2000-06-222009-12-07Coley Pharm Gmbh Combination of CpG and antibodies directed against CD19, CD20, CD22 or CD40 for the treatment or prevention of cancer
EP1175905A1 (en)2000-07-242002-01-30Societe Des Produits Nestle S.A.Nutritional Composition
FI116089B (en)*2000-07-272005-09-15Johan Tore Karlstroem Device and procedures for controls
CZ302087B6 (en)2000-07-282010-10-06F. Hoffmann-La Roche AgPharmaceutical composition containing orlistat along with bile acid sequestrant for use in treatment and prevention of obesity
NZ507152A (en)*2000-09-272001-06-29Hiltive Pty LtdWall cladding assembly with cladding having recesses along opposite sides to engage with flanges of support members
AU2002249885A1 (en)2000-11-172002-08-12Adolor CorporationDelta agonist analgesics
NZ543940A (en)2000-12-042008-04-30Primagen B VDetermining the ratio of genomic DNA and mtDNA or their related gene products with regards to determining the stage of an asymptomatic disease
JP2004521093A (en)2000-12-132004-07-15イーライ・リリー・アンド・カンパニー Long-term treatment plan using glucagon-like insulin stimulating peptide
US6693125B2 (en)*2001-01-242004-02-17Combinatorx IncorporatedCombinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
DE60234577D1 (en)2001-03-232010-01-14Shire Canada Inc PHARMACEUTICAL MIXTURE FOR THE TREATMENT OF CANCER CONTAINING DIOXOLANE NUCLEOSIDE ANALOGUE
US20040242523A1 (en)2003-03-062004-12-02Ana-Farber Cancer Institue And The Univiersity Of ChicagoChemo-inducible cancer gene therapy
JP2004527528A (en)2001-04-092004-09-09プロジェニクス・ファーマスーティカルズ・インコーポレイテッド Anti-CD19 immunotoxin
IL158527A0 (en)*2001-04-262004-05-12Control Delivery Sys IncSustained release drug delivery system containing codrugs
CA2449175A1 (en)*2001-06-052002-12-12University Of ChicagoUse of methylnaltrexone to treat immune suppression
CA2463733C (en)2001-08-312011-03-22Eugene A. WolteringInhibition of angiogenesis and destruction of angiogenic vessels with extracts of noni juice (morinda citrifolia)
EP2939696B1 (en)2001-10-182016-03-09Nektar TherapeuticsPolymer conjugates of opioid antagonists
US20030144312A1 (en)2001-10-302003-07-31Schoenhard Grant L.Inhibitors of ABC drug transporters in multidrug resistant cancer cells
WO2003037365A1 (en)*2001-11-012003-05-08The Johns Hopkins UniversityMethods and compositions for treating vascular leak using hepatocyte growth factor
EP1458710A4 (en)*2001-12-212005-04-20Merck & Co IncHeteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5
CA2475305A1 (en)2002-02-042004-02-19Jonathan MossUse of methylnaltrexone in treating gastrointestinal dysfunction in equines
US20050011468A1 (en)*2002-02-042005-01-20Jonathan MossUse of methylnaltrexone in treating gastrointestinal dysfunction in equines
US7074825B2 (en)2002-03-072006-07-11Huanbiao MoComposition and method for treating cancer
MXPA04008772A (en)2002-03-142004-12-06Euro Celtique SaNaltrexone hydrochloride compositions.
US20030191147A1 (en)2002-04-092003-10-09Barry ShermanOpioid antagonist compositions and dosage forms
US7355081B2 (en)2002-04-172008-04-08The University Of North Carolina At Chapel HillCurcumin analogues and uses thereof
AU2003273176A1 (en)2002-05-172003-12-12Board Of Regents, The University Of Texas SystemBeta-2-glycoprotein 1 is an inhibitor of angiogenesis
US7012100B1 (en)2002-06-042006-03-14Avolix Pharmaceuticals, Inc.Cell migration inhibiting compositions and methods and compositions for treating cancer
US6986901B2 (en)*2002-07-152006-01-17Warner-Lambert Company LlcGastrointestinal compositions
US20040010997A1 (en)*2002-07-172004-01-22Oren CloseGuides to align masonry walls defining apertures, and methods of use
US7160913B2 (en)*2002-09-132007-01-09Thomas Jefferson UniversityMethods and kit for treating Parkinson's disease
US7691374B2 (en)*2002-10-232010-04-06Health Research, Inc.Method for increasing the efficacy of anti-tumor agents by anti-endoglin antibody
DE60329520D1 (en)2002-11-082009-11-12Mallinckrodt Inc PROCESS FOR THE PREPARATION OF QUATERNARY N-ALKYL MORPHINAN ALKALOID SALTS
AU2003296954A1 (en)2002-12-132004-07-09The Regents Of The University Of CaliforniaAnalgesic combination comprising nalbuphine
WO2004054569A1 (en)*2002-12-162004-07-01Council Of Scientific And Industrial ResearchPharmaceutical composition containing brevifoliol for use in chemotherapeutic treatment of human beings
MXPA05009367A (en)2003-03-072005-11-04Lilly Co EliOpioid receptor antagonists.
HRP20150037T4 (en)2003-04-082022-09-02Progenics Pharmaceuticals, Inc. PHARMACEUTICAL FORMULATIONS CONTAINING METHYLNALTREXONE
MXPA05010819A (en)*2003-04-082006-03-30Progenics Pharm IncThe use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome.
US20040259899A1 (en)2003-04-082004-12-23Sanghvi Suketu P.Combination therapy for constipation
AU2004233846B2 (en)2003-04-292010-07-01Nalpropion Pharmaceuticals LlcCompositions for affecting weight loss
US6992193B2 (en)2003-06-102006-01-31Adolor CorporationSulfonylamino phenylacetamide derivatives and methods of their use
CA2529307C (en)*2003-06-132013-12-24Microbia, Inc.Methods and compositions for the treatment of gastrointestinal disorders
US7494979B2 (en)2003-06-132009-02-24Ironwood Pharmaceuticals, Inc.Method for treating congestive heart failure and other disorders
AU2003903387A0 (en)2003-07-022003-07-17Sirtex Medical LimitedCombination therapy for treatment of neoplasia
US7066888B2 (en)2003-10-292006-06-27Allez Physionix LtdMethod and apparatus for determining an ultrasound fluid flow centerline
US8946262B2 (en)2003-12-042015-02-03Adolor CorporationMethods of preventing and treating gastrointestinal dysfunction
US6984403B2 (en)*2003-12-042006-01-10Pfizer Inc.Azithromycin dosage forms with reduced side effects
WO2005087208A2 (en)*2004-03-102005-09-22Trustees Of Tufts CollegeSynergistic effect of compositions comprising carotenoids selected from lutein, beta-carotene and lycopene
TW200533339A (en)2004-03-162005-10-16Bristol Myers Squibb CoTherapeutic synergy of anti-cancer compounds
US6946556B1 (en)2004-05-212005-09-20Acura Pharmaceuticals, Inc.Preparation of opioid analgesics by a one-pot process
US7094775B2 (en)2004-06-302006-08-22Bone Care International, LlcMethod of treating breast cancer using a combination of vitamin D analogues and other agents
US7388008B2 (en)*2004-08-022008-06-17Ambrilia Biopharma Inc.Lysine based compounds
US20060063792A1 (en)*2004-09-172006-03-23Adolor CorporationSubstituted morphinans and methods of their use
EP1799713B1 (en)2004-09-232014-11-05VasGene Therapeutics, Inc.Polypeptide compounds for inhibiting angiogenesis and tumor growth
US20080103438A1 (en)2004-09-302008-05-01Prais Alfred WMethod For Reducing Or Eliminating Residue In A Glass Container And A Glass Container Made In Accordance Therewith
CN101137378A (en)2005-01-202008-03-05普罗热尼奇制药公司Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
EP1861096B1 (en)2005-03-072018-12-26The University of ChicagoUse of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en)2005-03-072013-09-03The University Of ChicagoUse of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (en)2005-05-252007-11-28Progenics Pharm Inc SYNTHESIS OF (S) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
AR057035A1 (en)2005-05-252007-11-14Progenics Pharm Inc SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
MX2007015262A (en)2005-06-032008-02-22Univ ChicagoModulation of microbial pathogen-host cell interactions.
US20080194611A1 (en)2005-06-032008-08-14Alverdy John CModulation of Cell Barrier Dysfunction
EP1901742A2 (en)2005-06-032008-03-26The University of ChicagoModulation of cell barrier dysfunction
JP2008544222A (en)2005-06-092008-12-04マリンクロッド・インコーポレイテッド Method for separation and purification of naltrexone by preparative chromatography
PE20070207A1 (en)*2005-07-222007-03-09Genentech Inc COMBINED TREATMENT OF TUMORS THAT EXPRESS HER
WO2007025383A1 (en)*2005-08-302007-03-08Queen's University At KingstonPotentiation of the therapeutic action of an opioid receptor agonist and/or inhibition or reversal of tolerance to an opioid receptoi agonists using an ultralow dose of an alpha-2 receptor antagonist
PL116330U1 (en)2005-10-312007-04-02Alza CorpMethod for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US20070259939A1 (en)2006-05-042007-11-08Accelerated TechnologiesUsing naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
EP2068840A2 (en)*2006-07-212009-06-17LAB International SRLHydrophobic abuse deterrent delivery system
TW200815451A (en)*2006-08-042008-04-01Wyeth Corp6-carboxy-normorphinan derivatives, synthesis and uses thereof
TWI489984B (en)2006-08-042015-07-01Wyeth Corp Formulations for parenteral delivery of compounds and uses thereof
TW200817048A (en)*2006-09-082008-04-16Wyeth CorpDry powder compound formulations and uses thereof
AU2007323718A1 (en)2006-11-222008-05-29Progenics Pharmaceuticals, Inc.Processes for synthesizing quaternary 4,5-epoxy-morphinan analogs and isolating their N-stereoisomers
BRPI0719327A2 (en)2006-11-222014-02-04Progenics Pharm Inc 4,5-EPOXY-MORFINAN ANALOG N-oxides
AU2007323573A1 (en)*2006-11-222008-05-29Progenics Pharmaceuticals, Inc.7,8-saturated-4,5-epoxy-morphinanium analogs
EP3064503A1 (en)2007-03-292016-09-07Progenics Pharmaceuticals, Inc.Peripheral opioid receptor antagonists and uses thereof
CN101801979A (en)2007-03-292010-08-11普罗热尼奇制药公司Crystalline forms of -N-methylnaltrexone bromide and uses thereof
WO2008121860A1 (en)*2007-03-292008-10-09WyethPeripheral opioid receptor and antagonists and uses thereof
US8471022B2 (en)2008-02-062013-06-25Progenics Pharmaceuticals, Inc.Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
CA2676881C (en)2008-09-302017-04-25WyethPeripheral opioid receptor antagonists and uses thereof

Also Published As

Publication numberPublication date
ES2570374T3 (en)2016-05-18
US20140142132A1 (en)2014-05-22
TW201504243A (en)2015-02-01
TW200902005A (en)2009-01-16
AU2008233129A1 (en)2008-10-09
TWI466671B (en)2015-01-01
CA2865661A1 (en)2008-10-09
AU2008233129B2 (en)2014-03-20
EP2137191B1 (en)2016-03-02
CA2682125A1 (en)2008-10-09
CL2008000905A1 (en)2008-08-22
US8546418B2 (en)2013-10-01
PA8774201A1 (en)2009-06-23
WO2008121348A3 (en)2009-06-18
EP3064503A1 (en)2016-09-07
JP2010522755A (en)2010-07-08
WO2008121348A8 (en)2009-08-27
JP5461386B2 (en)2014-04-02
JP2014065719A (en)2014-04-17
EP2137191B8 (en)2016-06-08
US8853232B2 (en)2014-10-07
TWI553009B (en)2016-10-11
CA2682125C (en)2015-06-16
PL2137191T3 (en)2016-12-30
MX2009010552A (en)2009-12-14
AR065877A1 (en)2009-07-08
CL2013001885A1 (en)2014-03-28
WO2008121348A2 (en)2008-10-09
PE20090700A1 (en)2009-07-13
US20110190331A1 (en)2011-08-04
EP2137191A2 (en)2009-12-30
AU2014203242A1 (en)2014-07-10
CA2865661C (en)2016-05-17

Similar Documents

PublicationPublication DateTitle
PE20130480A1 (en) HETEROCYCLIC COMPOUNDS AS ANTAGONISTS OF THE PERIPHERAL OPIOID RECEPTOR
PE20150671A1 (en) 5-HT3 RECEPTOR ANTAGONISTS
NO316309B1 (en) Opiate <kappa> receptor agonists, anti-cl degree agents, use and preparation thereof
PE20060259A1 (en) QUINUCLIDINE COMPOUNDS AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR
NZ600379A (en)Morphinan derivatives for the treatment of drug overdose
PE20110390A1 (en) COMPOSITION OF TAPENTADOL AND AN OPIOID ANTAGONIST
EA201100161A1 (en) QUINUCLIDINE CARBONATE DERIVATIVES AND THEIR MEDICAL COMPOSITIONS
JP2016503779A5 (en)
JP2017008088A5 (en)
PE20130340A1 (en) (R) -N- (3- (7-METHYL-1H-INDAZOL-5-IL) -1- (4-METHYLPIPERIDIN-4-IL) PIPERAZIN-1-IL) -1-OXOPROPAN-2-IL) - 4- (2-OXO-1,2-DIHYDROQUINOLIN-3-IL) PIPERIDINE-1-CARBOXAMIDE AS ANTAGONIST OF THE PEPTIDE RECEPTOR RELATED TO THE CALCITONIN GENE (CGRP)
NZ619972A (en)Peripheral opioid receptor antagonists and uses thereof
ATE484497T1 (en) SULFONYLBENZIMIDAZOLE DERIVATIVES
PE20081441A1 (en) SUBTYPE OF SELECTIVE AMIDAS OF DIAZABICICLOALKANES
EA201590873A1 (en) Compounds possessing the activity of antagonists of muscarinic receptors and agonists of beta2 adrenergic receptors
PE20071143A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING AN ACETYLCHOLINESTERASE INHIBITOR AND A 5-HYDROXITRIPTAMINE-6 ANTAGONIST
HRP20140768T1 (en)Peripheral opioid receptor antagonists and uses thereof
RU2011147516A (en) MULTI-LAYERED TABLET CONTAINING AN EFFEESCENT LAYER
PE20091035A1 (en) DERIVATIVES OF 2-AMINOPYRIMIDINE
PE20140703A1 (en) HETEROARYL DERIVATIVES AS MODULATORS OF NACHR ALPHA 7
FI3551619T3 (en)Compositions comprising methylphenidate-prodrugs, processes of making and using the same
PE20061195A1 (en) BENZIMIDAZOLE DERIVATIVE AS ANGIOTENSIN II ANTAGONIST
PE20110943A1 (en) SOLID ORAL FORMULATION OF ALISQUIREN
CR20110093A (en) [4- (5-aminomethyl-2-fluoro-phenyl) -piperidin-1-yl] - [7-fluoro-1- (2-methoxy-ethyl) -4-trifluoromethoxy-1h-indole-3-yl] - methanone as a mast cell tryptase inhibitor
PE20110422A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING OPIOID ANTAGONISTS
JO3442B1 (en)Antagonists of somatostatin receptor subtype 5 (sstr5)

Legal Events

DateCodeTitleDescription
FCRefusal

[8]ページ先頭

©2009-2025 Movatter.jp